Skip to main content

Table 1 Summary of BRAF inhibitor trials

From: Therapy for metastatic melanoma: the past, present, and future

Trial Patients RR% PFS
(months)
OS
(years)
Number
(Patients)
Summary
Phase 2
Ribas et al. [15]
Vemurafenib in previously treated metastatic melanoma 52 6.2 Not yet reached 132 Met primary end point of best overall survival target of 30% (95% CI: 43 to 61%)
Phase 3
Chapman et al. [16]
Vemurafenib
versus
dacarbazine in untreated metastatic melanoma
48
v
5
5.3
v
1.6
Not yet reached 675 Compared vemurafenib and dacarbazine with co-primary endpoints of overall survival and progression free survival.
84% vs 64% OS at 6 months (95% CI: 78 to 89)
  1. OS, overall survival; PFS, progression free survival; RR, response rate.